Objective To assess the efficacy of recombinant human growth hormone ( rhGH ) in idiopathic growth hormone deficient ( IGHD ) children of Anyang, Henan province. Methods A prospective study including 30 children [ 18 boys and 12 girls, with mean age of ( 12. 0 ± 1. 5 ) years and BA of ( 8. 5 ±2. 1 ) years ] was carried out. The enrolled children were treated with subcutaneous injection of rhGH ( 0. 15 ~0. 20 U ? kg~ ? d ) daily before sleep for six months. Results The mean height growth rate of the enrolled children increased from ( 3. 56 ± 0. 78 ) cm/year to ( 9. 87 ± 2. 11 ) cm/year ( P < 0. 01 ) . The mean HtSDSCA increased from ( -2. 01 ±0. 63 ) cm to ( - 1. 72 ±0. 58 ) cm. HtSDSBA increased from ( 0. 11 ± 0. 65 ) cm to ( 0. 28 ± 1. 21 ) cm. Conclusion rhGH appears to be effective and sate in treating growth hormone deficient ( IGHD ) children in Anyang, Henan province, without affecting adolescence.%目的 观察河南安阳地区重组人生长激素(rhGH)治疗少年儿童特发性矮小症的疗效.方法 30例特发性矮小症患儿,女12例,男18例,平均年龄为(12.0±1.5)岁;骨龄为(8.5±2.1)岁,给予0.15～0.20 U·kg-1·d-1,睡前1 h皮下注射,连续治疗6个月.结果 特发性矮小症患儿治疗前后生长速率由(3.56±0.78)cm/年增长为(9.87±2.11)cm/年,治疗前后比较差异有统计学意义(P＜0.01);年龄身高标准差分值由(-2.01±0.63)cm增长为(-1.72±0.58)cm,骨龄的身高标准差分值由(0.11±0.65)cm增长为(0.28±1.21)cm,治疗前后差异均有统计学意义(P＜0.05).结论 对于河南安阳人群,国产重组人生长激素能对特发性矮小症起到治疗作用,且不会引起青春期提前.
展开▼
